AEON Biopharma (AEON) Stock Price, News & Analysis

Company Overview

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Key Stats

• Today's Range: $0.58 to $0.65
• 50-Day Range: $0.53 to $1.10
• 52-Week Range: $0.52 to $17.17
• Volume: 164,552 shs
• Average Volume: 530,583 shs
• Market Capitalization: $25.98 million
• P/E Ratio: 3.61
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

AEON Biopharma Stock Analysis - MarketRank™

AEON Biopharma scored higher than 49% of companies evaluated by MarketBeat, and ranked 574th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AEON Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AEON Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AEON Biopharma are expected to grow in the coming year, from ($0.77) to ($0.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AEON Biopharma is 3.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.45.

Price to Earnings Ratio vs. Sector

The P/E ratio of AEON Biopharma is 3.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.58.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AEON.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AEON Biopharma does not currently pay a dividend.

Dividend Growth

AEON Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for AEON.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for AEON Biopharma this week, compared to 0 articles on an average week.

Search Interest

4 people have searched for AEON on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AEON Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.50% of the stock of AEON Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.78% of the stock of AEON Biopharma is held by institutions.

AEON Stock Analysis - Frequently Asked Questions

How have AEON shares performed this year?

AEON Biopharma's stock was trading at $7.20 at the start of the year. Since then, AEON stock has decreased by 91.0% and is now trading at $0.65.
View the best growth stocks for 2024 here.

When did AEON Biopharma IPO?

AEON Biopharma (AEON) raised $75 million in an initial public offering on Thursday, October 14th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

Who are AEON Biopharma's major shareholders?

AEON Biopharma's top institutional shareholders include Polar Asset Management Partners Inc. (9.20%), Geode Capital Management LLC (0.62%), Caprock Group LLC (0.16%) and HighTower Advisors LLC (0.06%).
View institutional ownership trends.

How do I buy shares of AEON Biopharma?

Shares of AEON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of AEON Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AEON Biopharma investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AEON
• Previous Symbol: NASDAQ:AEON
• CUSIP: N/A
• CIK: 1837607
• Web: www.aeonbiopharma.com
• Phone: 754-220-9229
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +669.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.18
• Trailing P/E Ratio: 3.61
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,630,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -994.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($4.12) per share
• Price / Book: -0.16

Miscellaneous

• Outstanding Shares: 39,971,000
• Free Float: 30,578,000
• Market Cap: $25.98 million
• Optionable: Not Optionable
• Beta: 0.19